NASDAQ · Shell Companies · USD

Drugs Made In America Acquisition Corp. (DMAA) Stock Analysis

Drugs Made In America Acquisition Corp. (DMAA) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

DMAA

$10.76

+$0.01 (+0.09%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMAA with… →

DMAA Key Statistics

As of Sep 4, 2026

Trading

Open: $10.76
Previous Close: $10.75
Day's Range: 10.75–10.77
52-Week Range: 10.23–10.77
Volume: 29.70K

Valuation

Market Cap: $261.22M
P/E Ratio: 59.78
EPS (ttm): 0.18

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $5.94M
Profit margin: 0.00%
Shares Outstanding: 24.28M
1-Year Return: +4.87%

Dividend and dates

Avg Volume: 25.35K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMAA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+3.72%
2025 (partial year)	+4.16%

As of September 4, 2026.

DMAA Valuation vs Shell Companies Median

Median of 587 stocks

Metric	DMAA	Shell Companies median	vs median
P/E	59.78	45.20	32% above
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Drugs Made In America Acquisition Corp. (DMAA) at $261.22M. The company sits in the Financial Services sector, in the Shell Companies industry.

Over the past 52 weeks the price has ranged from $10.23 to $10.77. DMAA last closed at $10.76 on September 4, 2026. That is +$0.01 (+0.09%) against the previous close. The latest close sits 5.18% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Net income for the same year was $5.94M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 0.18.

Valuation Assessment

On trailing earnings, the shares are priced at 59.78 times earnings. That is 32.26% above the Shell Companies median of 45.2. The medians here are taken across 587 Shell Companies companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 2.06%. Over the trailing twelve months the price has returned +4.87%. The stored price history starts on February 25, 2025, and the total return since then is +8.03%.

Growth & Income

No dividend is on file for DMAA.

So far in 2026 the price is +3.72%.

Peer Comparison

Drugs Made In America Acquisition Corp. (DMAA) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Drugs Made In America Acquisition Corp.	DMAA	$261.22M	59.8
Churchill Capital Corp XI	CCXI	$746.38M	—
Churchill Capital Corp X	CCCX	$711.00M	—
Drugs Made In America Acquisition II Corp.	DMII	$647.83M	35.1

The Shell Companies industry average P/E ratio is 45.2x. Drugs Made In America Acquisition Corp. trades at a P/E of 59.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

DMII

Drugs Made In America Acquisition II Corp.

$647.83M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.